Neuraltus' NP001 fails Phase II for ALS

Neuraltus Pharmaceuticals Inc. (San Bruno, Calif.) said NP001 missed the primary and secondary endpoints in a Phase II trial to treat amyotrophic lateral sclerosis (ALS). Data were presented at the American Academy of Neurology meeting in Los Angeles.

On the primary endpoint, there was no significant difference between NP001 and placebo in the change from baseline in mean ALS Functional Rating Scale-Revised (ALSFRS-R) score at six months (p=0.79). There was also no significant difference between NP001 and placebo on the secondary endpoint of improving mean slow vital capacity (SVC) from baseline to six months (p=0.65)...